Publication | Open Access

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases

Neuro-oncologyRet Inhibitor VandetanibMedicinePathologyBronchial NeoplasmMtor Inhibitor EverolimusAnti-cancer AgentCancer TreatmentCns ActivityPharmacologyLung Cancer